CCA
NERV icon

Catalyst Capital Advisors’s Minerva Neurosciences NERV Stock Holding History

Catalyst Capital Advisors’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-36,875
Closed -$1.78M – 505
2014
Q4 		$1.78M Hold
36,875
– – 0.21% 104
2014
Q3 		$1.78M Buy
+36,875
New +$1.96M 0.23% 99

Other funds holding NERV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Catalyst Capital Advisors's NERV Position: Q1 2015 in Review

Catalyst Capital Advisors sold out of Minerva Neurosciences (NERV) in Q1 2015, closing a stake of 36,875 shares — an estimated $1.78M sold.

Catalyst Capital Advisors first reported a position in NERV in Q3 2014 and held it in 2 quarters. The position peaked at $1.78M in Q3 2014. 15 funds tracked by Wall St. Rank hold NERV as of Q1 2015.

  • Catalyst Capital Advisors reported no remaining Minerva Neurosciences position as of Q1 2015 after selling out during the quarter.
  • Catalyst Capital Advisors sold 36,875 Minerva Neurosciences shares in Q1 2015, an estimated $1.78M.
  • Catalyst Capital Advisors first reported a position in Minerva Neurosciences in Q3 2014 and held it in 2 quarters.
  • Catalyst Capital Advisors's Minerva Neurosciences position peaked at $1.78M in Q3 2014.
  • 15 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q1 2015.

Based on Catalyst Capital Advisors's 13F filing for Q1 2015, filed 15 May 2015.